Investing
GSK to boost respiratory portfolio with $1.4 billion Aiolos Bio deal
© Reuters. FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – British drugmaker GSK on Tuesday said it would acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments.
The acquisition will help beef up GSK’s respiratory diseases portfolio, which is currently growing on the back of its respiratory syncytial virus (RSV) vaccine’s strong launch.
Founded in 2023, Aiolos is developing a drug ready to enter late stage trials for the treatment of adult patients with asthma.
Read the full article here
-
Side Hustles6 days ago
5 Things That Could Significantly Impact Your Company in 2025
-
Investing6 days ago
NFI Group surge after board reshaped with new appointments, chairperson By Investing.com
-
Side Hustles4 days ago
Microsoft Is About to Begin Job Cuts. Here’s Why.
-
Side Hustles7 days ago
How Failing 22 Times Paved the Way to My Success
-
Passive Income5 days ago
3 Challenges Entrepreneurs Will Face in 2025
-
Side Hustles5 days ago
The Canadian Media Lawsuit That Could Reshape Tech’s Future
-
Investing7 days ago
Apple Siri Settlement: Who Is Eligible for a Cash Payout
-
Side Hustles7 days ago
3 Strategies to Make Your Next Campaign Go Viral